Revvity Inc. $RVTY Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. lowered its position in Revvity Inc. (NYSE:RVTY) by 3.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,148 shares of the company’s stock after selling 201 shares during the quarter. Securian Asset Management Inc.’s holdings in Revvity were worth $595,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. HB Wealth Management LLC raised its holdings in Revvity by 4.8% during the first quarter. HB Wealth Management LLC now owns 2,494 shares of the company’s stock worth $264,000 after purchasing an additional 114 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Revvity by 25.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 694 shares of the company’s stock worth $73,000 after purchasing an additional 140 shares in the last quarter. Banque Transatlantique SA raised its holdings in Revvity by 19.4% during the first quarter. Banque Transatlantique SA now owns 925 shares of the company’s stock worth $90,000 after purchasing an additional 150 shares in the last quarter. Signaturefd LLC raised its holdings in Revvity by 9.7% during the first quarter. Signaturefd LLC now owns 1,830 shares of the company’s stock worth $194,000 after purchasing an additional 162 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Revvity by 3.8% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,139 shares of the company’s stock worth $544,000 after purchasing an additional 187 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Trading Up 1.4%

Revvity stock opened at $98.91 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33. The firm has a market cap of $11.48 billion, a price-to-earnings ratio of 41.91, a price-to-earnings-growth ratio of 3.25 and a beta of 0.98. Revvity Inc. has a 1 year low of $81.36 and a 1 year high of $129.50. The firm’s 50 day moving average price is $89.38 and its two-hundred day moving average price is $92.42.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.04. The firm had revenue of $720.28 million for the quarter, compared to analyst estimates of $711.26 million. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.22 earnings per share. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, research analysts predict that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 6th. Shareholders of record on Friday, January 16th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, January 16th. Revvity’s payout ratio is presently 11.86%.

Analyst Ratings Changes

RVTY has been the topic of several recent analyst reports. Guggenheim initiated coverage on Revvity in a report on Wednesday, October 15th. They set a “neutral” rating on the stock. Evercore ISI dropped their target price on Revvity from $108.00 to $106.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Raymond James Financial reissued an “outperform” rating and set a $115.00 target price (down previously from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Weiss Ratings cut Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 8th. Finally, Barclays decreased their price target on shares of Revvity from $110.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, October 2nd. Nine analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Revvity has an average rating of “Moderate Buy” and a consensus target price of $116.38.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.